Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVs-SIRT1-VEGF
- Development stage
- Preclinical
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
EVs-SIRT1-VEGF is an engineered biologic therapeutic consisting of extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (BMSCs). These EVs are modified with two functional modules: a SIRT1 protein module for therapeutic effect and a VEGF-targeting aptamer module for precision delivery. The SIRT1 protein is enriched in the EVs by overexpressing it in the source BMSCs using a recombinant adenovirus. The targeting module utilizes cholesterol-modified aptamers that bind to vascular endothelial growth factor (VEGF) on the surface of vascular endothelial cells (VECs). Once targeted to VECs, the EVs are internalized, releasing SIRT1 to activate the Nrf2 pathway and regulate oxidative stress, thereby reversing endothelial-mesenchymal transition (EndMT) and reducing inflammation in atherosclerotic plaques.
- Other names
- Engineered BMSC-derived EVsSIRT1-enriched VEGF-targeted EVsSIRT-1-enriched VEGF-targeted EVsSIRT 1-enriched VEGF-targeted EVs
02
Targets
SIRT1 (NAD-dependent protein deacetylase sirtuin-1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)Vascular endothelial growth factor/Vascular endothelial growth factor receptor 2 signaling axis
Beyond the preview
Go deeper on EVs-SIRT1-VEGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVs-SIRT1-VEGF.